Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis

Current Drug Discovery Technologies

Volumn 7, Issue 2, 2010, Pages 137-140

  Hebb, Andrea L O ^a   Bhan, Virender ^b   Wishart, Alexander D ^a   Moore, Craig S ^a   Robertson, George S ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

CSF; HK6; PPMS; RRMS; Serum; SPMS

Indexed keywords

KALLIKREIN 6;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 78649575448     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793180611     Document Type: Article

References (14)

1. Lassman H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 695-7.
2. Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 2003; 16: 267-73.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Medical progress: Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
4. Hebb AL, Moore CS, Bhan V, Robertson GS. Targeting apoptosis to treat multiple sclerosis. Curr Drug Discov Technol 2008; 5(1): 75-7.
5. Scarisbrick IA, Linbo R, Vandell AG, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008; 389(6), 739-45.
6. Terayama R, Bando Y, Jiang YP, Mitrovic B, Yoshida S. Differential expression of protease M/neurosin in oligodendrocytes and their progenitors in an animal model of multiple sclerosis. Neurosci Lett 2005; 382(1-2): 82-87.
7. Terayama R, Bando Y, Yamada M, Yoshida S. Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 2005; 52(2): 108-18.
8. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol 2006; 178: 167-76.
9. Marques A, Müller S. Mouse models of autoimmune diseases. Curr Drug Discov Technol 2009; 6(4): 262-69.
10. Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA. Targeting human kallikrein-related peptidase 6-proteolysis attenuates CNS inflammatory disease. FASEB J 2004; 18(7): 920-2.
11. Blaber SI, Yoon H, Scarisbrick IA, Juliano MA, Blaber M. The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry 2007; 46: 5209-17.
12. Diamandis EP, Yousef GM, Soosaipillai AR, et al. Immunofluorometric assay of human kallikrein-related peptidase 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000; 33(5): 369-75.
13. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikreinrelated peptidase 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21(6): 1035-43.
14. Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR. Human kallikrein-related peptidase 6 as a biomarker of Alzheimer's disease. Clin Biochem 2000; 33: 663-7.